RT Journal Article
SR Electronic
T1 Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population
JF Stroke and Vascular Neurology
JO Stroke Vasc Neurol
FD BMJ Publishing Group Ltd
SP 270
OP 278
DO 10.1136/svn-2020-000385
VO 5
IS 3
A1 Wang, Yilong
A1 Han, Shangrong
A1 Qin, Haiqiang
A1 Zheng, Huaguang
A1 Jiang, Bin
A1 Cao, Yong
A1 Gao, Yuan
A1 Guan, Ling
A1 Jia, Qian
A1 Jiang, Yong
A1 Jiao, Yuming
A1 Li, Shuya
A1 Li, Yapeng
A1 Li, Zixiao
A1 Liu, Wei
A1 Ru, Xiaojuan
A1 Sun, Dongling
A1 Sun, Haixin
A1 Wang, Penglian
A1 Wang, Tingting
A1 Zong, Lixia
A1 Guo, Lei
A1 Xie, Xuewei
A1 Xu, Yuming
A1 Xu, Yuyuan
A1 Yang, Xiaomeng
A1 Yang, Yingying
A1 Zhou, Mengyuan
A1 Wang, Wenzhi
A1 
YR 2020
UL http://svn.bmj.com/content/5/3/270.abstract
AB Aim Cerebrovascular disease is the leading cause of death and disability in China, causing a huge burden among patients and their families. Hence, stroke prevention is critical, especially in the high-risk population. Here, we present the evidence-based guideline suitable for the Chinese population.Methods Literature search of PubMed and Cochrane library (from January 1964 to June 2019) was done. After thorough discussion among the writing group members, recommendations were listed and summarised. This guideline was reviewed and discussed by the fellow writing committees of the Chinese Stroke Association’s Stroke.Results This evidence-based guideline was written in three parts: controlling the risk factors of stroke, utilisation of antiplatelet agents and assessing the risks of first-ever stroke. All recommendations were listed along with the recommending classes and levels of evidence.Conclusions This guideline provides recommendations for primary prevention of cerebrovascular disease among high-risk population in China. Controlling related risk factors, appropriately using antiplatelet agents, assessing the risk of developing first-ever stroke should help reduce the rate of cerebrovascular disease in China.